Prof. Brigette Ma






Name


Ma Buig Yue Brigette

Chinese Name


马碧如

Qualifications


Doctor of Medicine, Chinese University of Hong Kong
Fellow of the Hong Kong Academy of Medicine
Fellow of the Hong Kong College of Physicians (Medical Oncology)
Fellow of the Royal Australasian College of Physician (Internal Medicine, Medical Oncology)
Bachelor of Medicine and Bachelor of Surgery

Title


Professor (Clinical), CUHK
Honorary Consultant, Hong Kong Hospital Authority
Medical Director, Phase 1 Clinical Trial Centre, CUHK
Co-director of the Cancer Drug Testing Unit, Department of Clinical Oncology, CUHK
Honorary Professor, Department of Health Technology and Informatics, The Hong Kong Polytechnic University

Email


brigette@clo.cuhk.edu.hk

Specific Research / Sites of Interest


New drug development and clinical research: designing and conducting phase I clinical trials, novel therapies for nasopharyngeal carcinoma, colorectal cancer and other gastrointestinal cancers.
Translational research in novel therapeutics in nasopharyngeal carcinoma and hepatocellular carcinoma: preclinical evaluation of novel drugs and biomarkers of drug response. Examples including the targeting of histone deacetylases, hypoxia and angiogenesis, epidermal growth factor receptor and other tyrosine kinase-mediated signaling pathways.
The use of functional imaging (e.g. positron-emission tomography, dynamic-contrast magnetic resonance imaging) in the pharmacodynamic evaluation of novel therapies.


Short Biography


Dr Brigette Ma is currently Professor and Honorary Consultant at the Department of Clinical Oncology, Chinese University of Hong Kong, and Honorary Professor, Department of Health Technology and Informatics, The Hong Kong Polytechnic University. She is also the Medical Director of the Phase I Clinical Trial Centre (Oncology) and Co-Director of the Cancer Drug Testing Unit at the Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong. Dr Ma received her Bachelor of Medicine and Surgery with Honours at Monash University, Melbourne, Australia, and was awarded Fellow of the Royal Australasian College of Physicians in 2001, Fellow of Hong Kong College of Physicians in 2004, and Doctor of Medicine in 2014 (CUHK). She underwent post-graduate training in Medical Oncology at the Peter MacCallum Cancer Institute, Melbourne, and was Research Fellow at the Princess Margaret Hospital, Toronto, Canada. She has published over 110 peer-reviewed papers and contributed to three book chapters on subjects including head and neck cancers, colorectal cancer and phase I clinical trials. She is the Vice-President of the Hong Kong Nasopharyngeal Cancer Study Group and President of the Hong Kong Head and Neck Society. Dr Ma is a member of European Society of Medical Oncology (ESMO) Consensus Working Group for the management of metastatic colorectal cancer, a member of the International Advisory Board of the Lancet Oncology, and serves in the editorial board of the Asian-Pacific Journal of Clinical Oncology. She has been a member of the Joint Scientific Committee for Phase 1 Clinical Trials, Centre of Health Protection, Hong Kong Hospital Authority, and has served on numerous advisory boards of major pharmaceutical companies. She has been a Chair/ member of the Scientific/ Organizing committees of several local and international conferences, notably, the Scientific Committee at the 2016 American Association of Cancer Research at New Orleans, USA. Dr Ma has been a member of the Women in Cancer Research Council (WICR) of the American Aassociation of Cancer Research since 2016.

Most Representative Publications


Ma B, King AD, Leung L, Wang K, Poon A, Ho WM, Mo F, Chan CML, Chan ATC, Wong SCS. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer - a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol. 2017; 28(7):1576-81.

Li YY, Chung GT, Lui VW, TO KF, Ma BB, Chow C, Woo JK, Yip KY, Seo JS, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW*. Exome and genome sequencing of nasopharynx cancer identifies NF-KB pathway activating mutations. Nat Commun. 2017 Jan 18; 8:14121.

Chan KCA, Woo JKS, King A, Zee B, Lam JWK, Chan SL, Chu SW, Mak C, Tse I, Leung S, Chan G, Hui EP, Ma BBY, Chiu RWK, Leung SF, Van Hasselt A, Chan ATC, Lo YMD. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017; 377:513-22.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, K?hne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, ?sterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Ta?eb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold DArnold. European Society of Medical Oncology Consensus Guidelines for the management of patients with metastatic colorectal cancer – 2016. Ann Oncol 2016; 27(8):1386-422.

Li J, Qin SK, Xu R, Yau T, Ma BBY, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW, on behalf of the CONCUR Investigators. Regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(6):619-29.

Lee A, Ma B, Ng WT, Chan ATC. The management of nasopharyngeal carcinoma – current practice and future perspective. J Clin Oncol. 2015; 33(29):3356-64.

Ma B, Chan L, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray R, Wong C, KF To, King AD, Ahuja A, Chan ATC. Intermittent versus continuous erlotinib with concomitant modified ‘Xelox’ (q3W) in first-line treatment of metastatic colorectal cancer - correlation with serum amphiregulin and transforming growth factor receptor alpha. Cancer 2013; 119:4145-53.

Ma BBY, EP Hui, TSK Mok. Population-based differences in treatment outcome following anti-cancer drug therapies. Lancet Oncol. 2010; 11(1):75-84.

Ma BBY, EP Hui, SCC Wong, SY Tung, KK Yuen, A King, SL Chan, SF Leung, MK Kam, BKH Yu, B Zee, ATC Chan. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma - correlation with excision repair cross complementing-1 polymorphisms. Ann Oncol. 2009; 20 (11):1854-9.

Ma B, Bristow R, Kim J, Siu L. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003; 21(14)2760-76.